Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. - Wikidata - awgldk - TriplyDB

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.

http://www.wikidata.org/entity/Q43582725

about

Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting Potential therapeutic targets for neurokinin-1 receptor antagonists Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting Pharmacokinetic evaluation of fosaprepitant dimeglumine Aprepitant and fosaprepitant: a 10-year review of efficacy and safety Aprepitant--a novel NK1-receptor antagonist.Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis.Chemotherapy-related nausea and vomiting - past reflections, present practice and future management.Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.5-HT3 receptor antagonists for prevention of late acute-onset emesis.Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials.Employment of substandard antiemetic prophylaxis in recent trials of chemotherapy-induced nausea and vomiting.Aprepitant (EMEND): the role of substance P in nausea and vomiting.Emerging drugs for chemotherapy-induced emesis.Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting.Anti-emetic therapy in cancer chemotherapy: current status.Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients.Preparation and pharmacokinetic study of aprepitant-sulfobutyl ether-β-cyclodextrin complex.Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice.Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy.Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.Fall in plasma ghrelin concentrations after cisplatin-based chemotherapy in esophageal cancer patients.Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting.Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review.Anticipatory nausea in animal models: a review of potential novel therapeutic treatments.Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics.Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects.5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy.Using decision modeling to determine pricing of new pharmaceuticals: the case of neurokinin-1 receptor antagonist antiemetics for cancer chemotherapy.Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers.Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study.Effects of antioxidant herbs on chemotherapy-induced nausea and vomiting in a rat-pica model.

P2860

Q28258863-043B7505-1DCC-4F9C-8993-2AFF9D2EBE4E Q28262693-AF1B2E2A-0612-4194-BA89-D076972B5033 Q34239808-042B25F5-6B2B-445A-A56A-33580E22C4AF Q35163168-F3733D5C-1123-45E9-B33F-812103036B80 Q35345557-A33CF7DA-5B5C-4C70-A256-9B1311595ACC Q35594000-0B77C2D2-D996-4715-9C43-19BAB8CB0EC8 Q35594004-9AB5AFE6-3649-4ED5-AAEB-6B772BDA5EE8 Q35666500-7CDDB85C-FF1B-4A63-B072-7AF0F1114FF5 Q35779340-4A149A50-CAAB-4EB4-9AAE-D9ABF51BF1C8 Q35865448-33548058-8D62-4BAC-8E35-19D3521959FB Q35964412-0374C5FE-FB00-4231-877B-38C9A272FDB9 Q36276557-D73694DF-714F-445A-88D1-4B3AD27B60D3 Q36284018-B77A8241-AC57-4C83-9A18-CA0D6CE40D7B Q36407422-2B1CA62D-F1D4-4264-8675-69E5067F7383 Q36823546-D496F8BD-6590-449C-B81E-40AAF40BE8B9 Q36843470-06D7770D-986B-490D-87FE-36C50913CCD2 Q36909501-2FF2AB60-E36F-480F-B0C5-82CE30765F76 Q37316977-6459EFC1-0166-4D6A-97AE-64D1997358C7 Q37355479-7D79892F-64FF-43DE-B275-382D1DF56255 Q37538937-BD9A9829-2F82-417E-AB9C-5655F0B4F31D Q37677897-A6C13D91-9135-4689-821B-BE4A9BFE5C6E Q37783929-8042F501-6269-4FF3-99F6-D9B8AE141989 Q37857329-B893BDE5-EDCB-4EF4-8CB5-A12066B4D52F Q37902946-228AF171-7409-4016-8C40-3CCAE1894B8F Q37982438-7F3916C0-CEC9-474E-BDA0-F46FCA93D258 Q38036613-12B7A2A3-3A2B-46EF-9B48-88E2DFB0F5BB Q38208999-7DB67133-06FF-4C7E-9991-D706A1C76E41 Q42551206-6523C21B-EFFD-49BD-97F6-ED7B7FA5B22E Q42973034-68207D49-E76A-4FF7-9DC4-E947DEDF0B43 Q44062377-51064D36-0BA0-4D9E-8148-D3AC020F3BDC Q44571968-52A2796B-5E7F-4B54-A598-FC613F0684C6 Q44925317-AC1E17ED-E727-4242-A5FE-8E02A69346F0 Q45077382-8B0F0EFE-BA52-4135-B039-1FF628EB83C5 Q46954375-E42100B9-4BEF-4039-8543-15AED6B7C212 Q48491599-6920EE7C-5559-4C3B-87C6-E6F19E387BC1 Q51239101-C18D6723-4743-4519-A621-6A638CC56D19

P2860

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.

http://www.wikidata.org/entity/Q43582725

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh-hant

name

Comparison of L-758,298, a pro ...... n of cisplatin-induced emesis.

@en

Comparison of L-758,298, a pro ...... n of cisplatin-induced emesis.

@nl

type

label

Comparison of L-758,298, a pro ...... n of cisplatin-induced emesis.

@en

Comparison of L-758,298, a pro ...... n of cisplatin-induced emesis.

@nl

prefLabel

Comparison of L-758,298, a pro ...... n of cisplatin-induced emesis.

@en

Comparison of L-758,298, a pro ...... n of cisplatin-induced emesis.

@nl

P1433

Q43582725-EA242058-9DB6-4D79-AD76-A6355A4BCCA8

P1476

Q43582725-E3A04804-20FC-45F4-A9C5-7F906F8C6B19

P2093

Q43582725-0594B7AD-3146-4F9B-BFB8-6BC8513501BD

Q43582725-063C5D81-3D03-4980-BA41-0A3037265322

Q43582725-0DE2AEC6-579C-455A-8CE6-26710377F6F2

Q43582725-13ACE204-966D-4A70-9998-C9D4D27D3448

Q43582725-2C015E64-D2DC-4FC5-A71C-179B910E686C

Q43582725-5146DF25-CF89-4BE2-BA98-76A02FDCDB93

Q43582725-5ED2E7F4-1C5D-4965-AFB3-9BA5129D1FF6

Q43582725-87EDE703-7648-4061-B1B4-0B4E24867C5A

Q43582725-C3C6E55F-DAD2-430B-B7E6-742E5A827DCB

Q43582725-DF1155BD-C20A-44ED-B140-84007FC6434D

P304

Q43582725-596D2E98-3C70-46C8-819D-1087F0D42F52

P31

Q43582725-2490A9FE-1411-4B9C-BA7C-C5960B25D55A

P356

Q43582725-EAF09325-D5FC-4A6E-819C-89CB7368A569

P433

Q43582725-DC4AE6BE-1A0F-4E8F-A037-4D8E6176C873

P478

Q43582725-52B2A05E-85CC-4FAA-85A6-5BF197B4F054

P577

Q43582725-33055749-6AC9-4D1F-A299-F308112AE5C6

P698

Q43582725-635814F7-9BAB-44F2-B7EF-33EAD1E35F43

P356

S0959-8049(00)00416-0

P1433

European Journal of Cancer

P1476

Comparison of L-758,298, a pro ...... n of cisplatin-induced emesis.

@en

P2093

Borms M

http://www.w3.org/2001/XMLSchema#string

Carides AD

http://www.w3.org/2001/XMLSchema#string

Cocquyt V

http://www.w3.org/2001/XMLSchema#string

De Smet M

http://www.w3.org/2001/XMLSchema#string

Decramer ML

http://www.w3.org/2001/XMLSchema#string

Eldridge K

http://www.w3.org/2001/XMLSchema#string

Gertz BJ

http://www.w3.org/2001/XMLSchema#string

O'Brien M

http://www.w3.org/2001/XMLSchema#string

Reinhardt RR

http://www.w3.org/2001/XMLSchema#string

Schellens JH

http://www.w3.org/2001/XMLSchema#string

P304

835-842

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0959-8049(00)00416-0

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P577

2001-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11313170

http://www.w3.org/2001/XMLSchema#string